{"id":11339,"date":"2025-11-03T21:20:28","date_gmt":"2025-11-03T20:20:28","guid":{"rendered":"https:\/\/oxfordwisefinance.com\/blog\/?p=11339"},"modified":"2025-11-03T21:21:44","modified_gmt":"2025-11-03T20:21:44","slug":"6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal","status":"publish","type":"post","link":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/","title":{"rendered":"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal"},"content":{"rendered":"

<\/p>\n

In September, the competition for acquiring the metabolic medicines<\/a><\/b> biotech company Metsera<\/b> heated up, ultimately narrowing down to two major pharmaceutical players. Despite a higher bid from Novo Nordisk<\/b>, Pfizer<\/a><\/b> clinched the deal with a $4.9 billion offer, largely due to regulatory and financial uncertainties associated with a potential merger with the Danish firm. However, Novo has returned with a fresh unsolicited offer. This latest proposal mirrors the previous one but promises significantly more upfront cash for Metsera’s shareholders.<\/p>\n

Recently, Metsera announced its readiness to depart from the Pfizer deal, stating that it has determined Novo\u2019s new offer to be more advantageous. Novo’s plan involves a cash payment of $56.50 for each Metsera share, totaling around $6.5 billion. This price represents a remarkable 69% premium compared to Metsera’s stock price on September 19, the last trading day prior to Pfizer’s acquisition announcement. Additional payments are linked to the achievement of specified milestones.<\/p>\n

Although Pfizer is contesting Novo’s offer, it is not doing so with a higher monetary value. The New York-based pharmaceutical company claims that Novo’s proposal does not meet the criteria of a superior offer as defined in its acquisition agreement with Metsera. Pfizer insists it will uphold its legal entitlements under this agreement.<\/p>\n

Metsera is in the process of developing innovative obesity drugs<\/b> that fall within the same category of medications as Novo Nordisk\u2019s Wegovy<\/a><\/b>, a peptide-based treatment that simulates gut hormones to induce metabolic changes conducive to weight loss. However, Metsera\u2019s GLP-1 drugs may provide advantages in dosing and manufacturing over both Wegovy and Eli Lilly<\/b>\u2019s Zepbound<\/b>, which currently dominate the market. Furthermore, the biotech is exploring pill formulations and targeting additional obesity-related objectives. In an increasingly competitive obesity treatment landscape, Metsera\u2019s initiatives could distinguish themselves, making them appealing to any firm eager to establish a footprint in the metabolic medicines<\/b> sector.<\/p>\n

According to regulatory filings connected to the Pfizer acquisition agreement, Novo was one of as many as eight companies that engaged with Metsera over the past year regarding a possible deal. Known as \u201cParty 1,\u201d Novo demonstrated early and consistent interest. However, Metsera expressed concerns about the regulatory risks associated with a potential alliance with Novo, specifically that the merger might not pass the scrutiny of antitrust regulators. Due to this risk, the company articulated that \u201cMetsera would need to be significantly compensated if it could agree to a transaction with such risks at all,\u201d as indicated in the filings.<\/p>\n

Novo\u2019s latest offer is structured in two phases. The initial payment of $56.50 in cash for each Metsera share would be made immediately upon signing a definitive agreement, prior to any regulatory approval. In return, Metsera would issue Novo non-voting preferred stock representing 50% of its share capital. Subsequently, Metsera would declare a cash dividend of $56.50 per share to shareholders within ten days following the agreement.<\/p>\n

Once both shareholder and regulatory approvals are obtained, the acquisition would move to the second phase. Metsera shareholders would be eligible for a contingent value right (CVR) that could yield up to $21.25 per share in cash, based on specific development and regulatory approval milestones. Novo would then acquire the remaining outstanding shares of Metsera. The milestones outlined for the CVR are akin to those in the Pfizer agreement and could potentially add around $2.5 billion to the overall deal if all targets are achieved. Although the proposed up to $21.25 per share from Novo is significantly lower than the up to $37 CVR payment suggested in September, it aligns more closely with Pfizer\u2019s CVR terms.<\/p>\n

Aside from financial figures, Novo\u2019s new proposal is fundamentally similar to the deal that Metsera\u2019s board previously rejected in September. The board acknowledged that this deal structure offered greater value to the company\u2019s shareholders than a standard termination fee that would be payable should the deal fall through due to regulatory challenges. Nevertheless, Metsera’s board opted against Novo\u2019s September offer, citing concerns that regulatory hurdles could delay deal closure by as much as two years, with CVR payments only being made after an extended period, if they occur at all.<\/p>\n

Factors influencing the board’s preference for Pfizer\u2019s offer included the certainty of the financial terms provided by Pfizer and the anticipated speed of the deal’s completion. Pfizer projected that the transaction would close in the fourth quarter of this year. Ultimately, Metsera\u2019s board voted to accept Pfizer\u2019s offer of $47.50 per share, totaling approximately $4.9 billion.<\/p>\n

In a research note released on Thursday, analyst David Risinger from Leerink Partners<\/b> pointed out the uncertainty surrounding Novo\u2019s confidence that antitrust regulators would approve its acquisition of Metsera, considering Novo and Lilly\u2019s dominance in the market for metabolic drugs that mimic gut hormones. Additionally, the Trump administration’s \u201cAmerica First\u201d policies may also influence regulatory scrutiny of a potential Novo deal for Metsera.<\/p>\n

In its statement responding to Novo\u2019s new offer for Metsera, Pfizer characterized the proposal as an attempt by a dominant market player to suppress competition through the acquisition of an American competitor. Pfizer argues that the structure of the deal appears designed to circumvent antitrust regulations and comes with associated regulatory and execution risks.<\/p>\n

\u201cThe proposal is illusory and cannot qualify as a superior proposal under Pfizer\u2019s agreement with Metsera, and Pfizer is prepared to pursue all legal avenues to enforce its rights under its agreement,\u201d stated the pharmaceutical giant.<\/p>\n

Like many mergers and acquisitions, Pfizer\u2019s agreement with Metsera contains a clause prohibiting the biotech from soliciting other offers. However, the agreement allows Metsera to respond to unsolicited higher bids. In addition to providing greater value to shareholders, the agreement characterizes a superior company proposal as one that considers all terms and conditions, including all financial, regulatory, financing, conditionality, legal, and other terms.<\/p>\n

Currently, Pfizer\u2019s agreement with Metsera remains active. However, Metsera’s notification of its intent to enter a definitive agreement with a superior offer grants Pfizer four business days to modify its deal terms. Should Metsera terminate the Pfizer agreement to accept Novo\u2019s proposal, the agreement stipulates that the biotech must pay a termination fee of $190 million to the pharmaceutical company.<\/p>\n

For more on the latest developments in litigation, regulation, deals, and financial services trends, subscribe to Finance Docket<\/b>, a collaboration between Breaking Media publications Above the Law and Dealbreaker.<\/em><\/p>\n

Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

In September, the competition for acquiring the metabolic medicines biotech company Metsera […]<\/p>\n","protected":false},"author":1,"featured_media":11340,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pagelayer_contact_templates":[],"_pagelayer_content":"","iawp_total_views":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[142,819],"tags":[],"class_list":["post-11339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance-business","category-pharmaceutical-industry","col-md-12"],"yoast_head":"\n$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal - Blog - Oxford Wise Finance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal - Blog - Oxford Wise Finance\" \/>\n<meta property=\"og:description\" content=\"In September, the competition for acquiring the metabolic medicines biotech company Metsera […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Oxford Wise Finance\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/instantpaydayloans\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T20:20:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-03T20:21:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"776\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oxfordwisefinance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/OxfordWiseLoans\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/\"},\"author\":{\"name\":\"Oxfordwisefinance\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"headline\":\"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal\",\"datePublished\":\"2025-11-03T20:20:28+00:00\",\"dateModified\":\"2025-11-03T20:21:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/\"},\"wordCount\":1068,\"commentCount\":2,\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1\",\"articleSection\":[\"Finance & Business\",\"Pharmaceutical Industry\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/\",\"name\":\"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal - Blog - Oxford Wise Finance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1\",\"datePublished\":\"2025-11-03T20:20:28+00:00\",\"dateModified\":\"2025-11-03T20:21:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1\",\"width\":1200,\"height\":776},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\",\"name\":\"Blog - Oxford Wise Finance\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\",\"name\":\"Oxfordwisefinance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"caption\":\"Oxfordwisefinance\"},\"sameAs\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/\",\"https:\\\/\\\/www.facebook.com\\\/instantpaydayloans\",\"https:\\\/\\\/x.com\\\/https:\\\/\\\/x.com\\\/OxfordWiseLoans\"],\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal - Blog - Oxford Wise Finance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/","og_locale":"en_US","og_type":"article","og_title":"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal - Blog - Oxford Wise Finance","og_description":"In September, the competition for acquiring the metabolic medicines biotech company Metsera […]","og_url":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/","og_site_name":"Blog - Oxford Wise Finance","article_author":"https:\/\/www.facebook.com\/instantpaydayloans","article_published_time":"2025-11-03T20:20:28+00:00","article_modified_time":"2025-11-03T20:21:44+00:00","og_image":[{"width":1200,"height":776,"url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1","type":"image\/jpeg"}],"author":"Oxfordwisefinance","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/OxfordWiseLoans","twitter_misc":{"Written by":false,"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/#article","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/"},"author":{"name":"Oxfordwisefinance","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"headline":"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal","datePublished":"2025-11-03T20:20:28+00:00","dateModified":"2025-11-03T20:21:44+00:00","mainEntityOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/"},"wordCount":1068,"commentCount":2,"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1","articleSection":["Finance & Business","Pharmaceutical Industry"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/","url":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/","name":"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal - Blog - Oxford Wise Finance","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/#primaryimage"},"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1","datePublished":"2025-11-03T20:20:28+00:00","dateModified":"2025-11-03T20:21:44+00:00","author":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"breadcrumb":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/#primaryimage","url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1","contentUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1","width":1200,"height":776},{"@type":"BreadcrumbList","@id":"https:\/\/oxfordwisefinance.com\/blog\/6-5b-bid-by-novo-nordisk-to-outmaneuver-pfizer-in-obesity-deal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxfordwisefinance.com\/blog\/"},{"@type":"ListItem","position":2,"name":"$6.5B Bid by Novo Nordisk to Outmaneuver Pfizer in Obesity Deal"}]},{"@type":"WebSite","@id":"https:\/\/oxfordwisefinance.com\/blog\/#website","url":"https:\/\/oxfordwisefinance.com\/blog\/","name":"Blog - Oxford Wise Finance","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxfordwisefinance.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36","name":"Oxfordwisefinance","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","caption":"Oxfordwisefinance"},"sameAs":["https:\/\/oxfordwisefinance.com\/","https:\/\/www.facebook.com\/instantpaydayloans","https:\/\/x.com\/https:\/\/x.com\/OxfordWiseLoans"],"url":"https:\/\/oxfordwisefinance.com\/blog\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Novo-Nordisk-Swoops-In-With-65B-Bid-to-Top-Pfizers.jpg?fit=1200%2C776&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/comments?post=11339"}],"version-history":[{"count":2,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11339\/revisions"}],"predecessor-version":[{"id":11342,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11339\/revisions\/11342"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media\/11340"}],"wp:attachment":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media?parent=11339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/categories?post=11339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/tags?post=11339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}